Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477503 · ClinicalTrials.gov registry record · Phase 1
Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00477503: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00477503 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00477503, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
* Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging. * Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during remission of leptomeningeal metastasis (LM) and during LM occurrence, remission and recurrence.
Interventions
- DRUG Gallium-67 Citrate (Ga-67)
- DRUG In-111 DTPA (In-111 pentetate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477503
The ClinicalTrials.gov registry entry for NCT00477503 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gallium-67 Citrate (Ga-67) is the first listed.
NCT00477503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477503 about?
NCT00477503 is a clinical study titled "Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA". * Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging. * Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during remission o...
What is the current status of trial NCT00477503?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00477503?
The interventions under investigation include: Gallium-67 Citrate (Ga-67) (DRUG), In-111 DTPA (In-111 pentetate) (DRUG).
Who is sponsoring clinical trial NCT00477503?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.